27563006|t|Anti-nociceptive roles of the glia -specific metabolic inhibitor fluorocitrate in paclitaxel - evoked neuropathic pain
27563006|a|Paclitaxel (Taxol) is a powerful chemotherapy drug used in breast cancers, but it often causes neuropathic pain, leading to the early cessation of therapy and poor treatment outcomes. Approaches for the management of paclitaxel - induced neuropathic pain are urgently needed. The involvement of spinal astrocytes in the pathogenesis of paclitaxel - induced neuropathy has been reported, but little is known about the role of fluorocitrate (FC), a selective inhibitor of astrocyte activation, during neuropathic pain related to paclitaxel treatment. In this study, we investigated the effects of FC on paclitaxel - induced neuropathic pain. Glial fibrillary acidic protein (GFAP) expression was determined to assess astrocyte activation. To explore the mechanisms involved, the expression of glial glutamate transporter 1 (GLT-1) and the activation of mitogen-activated protein kinases in the spinal dorsal horn were analyzed. The results showed that paclitaxel decreased the mechanical nociceptive thresholds and increased GFAP expression, leading to spinal astrocyte activation. After paclitaxel treatment, GLT-1 was significantly down-regulated, and the phosphorylation of ERK1 / 2 and JNK were obviously up-regulated. However, paclitaxel treatment did not increase p38 phosphorylation. Additional studies showed that paclitaxel - evoked mechanical hypersensitivity was reduced by FC treatment. Moreover, FC treatment inhibited the activation of astrocytes and reversed the changes in GLT-1 expression and MAPK phosphorylation. Further study indicated that FC did not influence the antitumor effect of paclitaxel, suggesting that FC blocked paclitaxel - induced neuropathic pain without antagonizing its antitumor effect. Together, these results suggested that paclitaxel induced astrocyte-specific activation, which may contribute to mechanical allodynia and hyperalgesia, and that FC could be a potential therapeutic agent for paclitaxel - induced neuropathic pain.
27563006	0	22	Anti-nociceptive roles	T033	C0243095
27563006	30	34	glia	T025	C0027836
27563006	45	64	metabolic inhibitor	T044	C0021469
27563006	65	78	fluorocitrate	T109,T130	C0060559
27563006	82	92	paclitaxel	T109,T121	C0144576
27563006	95	101	evoked	T080	C1444748
27563006	102	118	neuropathic pain	T033	C3714625
27563006	119	129	Paclitaxel	T109,T121	C0144576
27563006	131	136	Taxol	T109,T121	C0678133
27563006	152	164	chemotherapy	T061	C3665472
27563006	165	169	drug	T121	C1254351
27563006	178	192	breast cancers	T191	C0678222
27563006	214	230	neuropathic pain	T033	C3714625
27563006	253	262	cessation	T052	C1880019
27563006	266	273	therapy	T061	C0087111
27563006	283	301	treatment outcomes	T080	C0085415
27563006	322	332	management	T058	C0376636
27563006	336	346	paclitaxel	T109,T121	C0144576
27563006	349	356	induced	T169	C0205263
27563006	357	373	neuropathic pain	T033	C3714625
27563006	378	386	urgently	T079	C0439609
27563006	399	410	involvement	T169	C1314939
27563006	414	420	spinal	T023	C0037925
27563006	421	431	astrocytes	T025	C0004112
27563006	439	451	pathogenesis	T046	C0699748
27563006	455	465	paclitaxel	T109,T121	C0144576
27563006	468	475	induced	T169	C0205263
27563006	476	486	neuropathy	T047	C0442874
27563006	544	557	fluorocitrate	T109,T130	C0060559
27563006	559	561	FC	T109,T130	C0060559
27563006	576	585	inhibitor	T080	C1999216
27563006	589	609	astrocyte activation	T043	C1326121
27563006	618	634	neuropathic pain	T033	C3714625
27563006	646	656	paclitaxel	T109,T121	C0144576
27563006	657	666	treatment	T061	C0087111
27563006	676	681	study	T062	C2603343
27563006	686	698	investigated	T169	C1292732
27563006	703	710	effects	T080	C1280500
27563006	714	716	FC	T109,T130	C0060559
27563006	720	730	paclitaxel	T109,T121	C0144576
27563006	733	740	induced	T169	C0205263
27563006	741	757	neuropathic pain	T033	C3714625
27563006	759	790	Glial fibrillary acidic protein	T116,T123	C0017626
27563006	792	796	GFAP	T116,T123	C0017626
27563006	798	808	expression	T045	C1171362
27563006	813	823	determined	T080	C0521095
27563006	827	833	assess	T058	C0184514
27563006	834	854	astrocyte activation	T043	C1326121
27563006	871	881	mechanisms	T169	C0441712
27563006	882	890	involved	T169	C1314939
27563006	896	906	expression	T045	C1171362
27563006	910	915	glial	T025	C0027836
27563006	916	939	glutamate transporter 1	T116,T123	C0061467
27563006	941	946	GLT-1	T116,T123	C0061467
27563006	956	966	activation	T045	C0599177
27563006	970	1003	mitogen-activated protein kinases	T116,T126	C0752312
27563006	1011	1029	spinal dorsal horn	T023	C0228564
27563006	1035	1043	analyzed	T062	C0936012
27563006	1049	1056	results	T169	C1274040
27563006	1069	1079	paclitaxel	T109,T121	C0144576
27563006	1094	1116	mechanical nociceptive	T039	C3893396
27563006	1117	1127	thresholds	T080	C0449864
27563006	1142	1146	GFAP	T116,T123	C0017626
27563006	1147	1157	expression	T045	C1171362
27563006	1170	1176	spinal	T023	C0037925
27563006	1177	1197	astrocyte activation	T043	C1326121
27563006	1205	1215	paclitaxel	T109,T121	C0144576
27563006	1216	1225	treatment	T061	C0087111
27563006	1227	1232	GLT-1	T116,T123	C0061467
27563006	1237	1250	significantly	T078	C0750502
27563006	1251	1265	down-regulated	T044	C0013081
27563006	1275	1290	phosphorylation	T044	C0031715
27563006	1294	1298	ERK1	T116,T126	C0082529
27563006	1301	1302	2	T116,T126	C0170168
27563006	1307	1310	JNK	T116,T126	C0248813
27563006	1326	1338	up-regulated	T044	C0041904
27563006	1349	1359	paclitaxel	T109,T121	C0144576
27563006	1360	1369	treatment	T061	C0087111
27563006	1387	1390	p38	T116,T126	C1120843
27563006	1391	1406	phosphorylation	T044	C0031715
27563006	1419	1426	studies	T062	C2603343
27563006	1439	1449	paclitaxel	T109,T121	C0144576
27563006	1452	1458	evoked	T080	C1444748
27563006	1459	1469	mechanical	T169	C0443254
27563006	1470	1486	hypersensitivity	T046	C0020517
27563006	1491	1498	reduced	T080	C0392756
27563006	1502	1504	FC	T109,T130	C0060559
27563006	1505	1514	treatment	T061	C0087111
27563006	1526	1528	FC	T109,T130	C0060559
27563006	1529	1538	treatment	T061	C0087111
27563006	1539	1548	inhibited	T080	C1999216
27563006	1553	1577	activation of astrocytes	T043	C1326121
27563006	1582	1590	reversed	T169	C1555029
27563006	1606	1611	GLT-1	T116,T123	C0061467
27563006	1612	1622	expression	T045	C1171362
27563006	1627	1631	MAPK	T116,T126	C0752312
27563006	1632	1647	phosphorylation	T044	C0031715
27563006	1657	1662	study	T062	C2603343
27563006	1678	1680	FC	T109,T130	C0060559
27563006	1703	1719	antitumor effect	T033	C0243095
27563006	1723	1733	paclitaxel	T109,T121	C0144576
27563006	1751	1753	FC	T109,T130	C0060559
27563006	1762	1772	paclitaxel	T109,T121	C0144576
27563006	1775	1782	induced	T169	C0205263
27563006	1783	1799	neuropathic pain	T033	C3714625
27563006	1825	1841	antitumor effect	T033	C0243095
27563006	1859	1866	results	T169	C1274040
27563006	1882	1892	paclitaxel	T109,T121	C0144576
27563006	1893	1900	induced	T169	C0205263
27563006	1901	1930	astrocyte-specific activation	T043	C1326121
27563006	1956	1976	mechanical allodynia	T184	C2936719
27563006	1981	1993	hyperalgesia	T184	C0020429
27563006	2004	2006	FC	T109,T130	C0060559
27563006	2018	2027	potential	T080	C3245505
27563006	2028	2045	therapeutic agent	T121	C1611640
27563006	2050	2060	paclitaxel	T109,T121	C0144576
27563006	2063	2070	induced	T169	C0205263
27563006	2071	2087	neuropathic pain	T033	C3714625